Item 1.02. Termination of a Material Definitive Agreement.
As previously disclosed, on March 30, 2021, F-star Therapeutics, Inc. (the
"Company") entered into a Sales Agreement (the "Sales Agreement") with SVB
Leerink LLC ("SVB Leerink") with respect to an "at-the-market" offering program
under which the Company could offer and sell, from time to time at the Company's
sole discretion, shares of its common stock, par value $0.0001 per share (the
"Common Stock"), having an aggregate offering price of up to $50 million,
through SVB Leerink as its sales agent.
On May 6, 2021, the Company delivered written notice to SVB Leerink to terminate
the Sales Agreement pursuant to Section 11(b) thereof, which the parties agreed
to make immediately effective.
A copy of the Sales Agreement was filed as Exhibit 1.2 to the Company's
Registration Statement on Form S-3 (File No. 333-254884), filed with the
Securities and Exchange Commission on March 31, 2021 and declared effective on
April 9, 2021.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
F-STAR THERAPEUTICS, INC. 
